文献速递肾小球疾病急性肾损伤

血浆半乳糖缺陷型IgA1与IgA血管炎肾炎患者肾功能丧失

Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis.
PubMed 文献 · Nephrol Dial Transplant · 2020-01-01

该队列研究纳入112例IgA血管炎肾炎(IgAV-N)、15例无肾脏受累的IgA血管炎及108例IgA肾病患者,检测肾活检时血浆Gd-IgA1水平。结果显示IgAV-N与IgA肾病患者Gd-IgA1均高于健康对照及无肾脏受累的IgAV患者,且校正临床资料后高Gd-IgA1独立关联肾功能衰竭风险增高。

要点

  • IgAV-N患者血浆Gd-IgA1水平与IgA肾病患者相似,均高于健康对照。
  • Gd-IgA1每增加1个标准差,肾功能衰竭风险独立增加(HR=1.703)。
  • 最高Gd-IgA1四分位组较最低组肾功能不良结局风险显著增高(HR=3.740)。

核心结论

  • 成人IgAV-N与IgA肾病患者Gd-IgA1水平相似升高。
  • Gd-IgA1水平升高与IgAV-N发生及进展相关,与IgA肾病中所见一致。

研究设计与样本

  • 队列研究纳入112例IgAV-N、15例无肾脏受累IgAV及108例IgA肾病患者。
  • 肾活检时用酶联免疫吸附法检测血浆IgA1与Gd-IgA1水平。
  • 主要终点为eGFR下降30%或终末期肾病或死亡。

主要发现

  • IgAV-N与IgA肾病患者Gd-IgA1均高于健康对照(302.86±54.93 vs 303.16±59.43 vs 281.30±43.74 U/mL,P=0.047)。
  • IgAV-N与IgA肾病患者Gd-IgA1均高于无肾脏受累IgAV患者(272.65±53.14 U/mL,P=0.036)。
  • 校正临床数据后,Gd-IgA1每1个标准差与肾功能衰竭风险独立相关(HR=1.703,95%CI 1.233-2.352,P=0.001)。
  • 与第一四分位组比,第四四分位组对不良肾脏结局保留预测价值(HR=3.740,95%CI 1.204-11.619,P=0.023)。

临床怎么用

  • 在IgAV-N患者中可检测血浆Gd-IgA1以辅助评估肾脏预后风险。
  • Gd-IgA1较高者需更密切监测肾功能,警惕进展至肾功能衰竭。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immunoglobulin A (IgA) vasculitis nephritis (IgAV-N) is the most common secondary IgA nephropathy (IgAN). Many studies have demonstrated that galactose-deficient IgA1 (Gd-IgA1) in the IgA1 hinge region is associated with the development and also progression of primary IgAN. In this study, we aimed to evaluate the roles of Gd-IgA1 in kidney disease progression in a large Chinese cohort of IgAV-N patients. METHODS: This cohort study enrolled 112 patients with IgAV-N, 15 patients with IgA vasculitis (IgAV) without kidney involvement and 108 patients with IgAN. Plasma IgA1 and Gd-IgA1 levels at kidney biopsy were measured by enzyme-linked immunosorbent assay. The primary endpoint was a 30% decline in estimated glomerular filtration rate or end-stage renal disease or death. RESULTS: The levels of Gd-IgA1 in IgAV-N and IgAN patients were higher than in healthy controls (mean ± SD, 302.86 ± 54.93 U/mL versus 303.16 ± 59.43 U/mL versus 281.30 ± 43.74 U/mL, respectively; P = 0.047), as well as compared with those with IgAV without kidney involvement (272.65 ± 53.14 U/mL; P = 0.036). After adjusting clinical data, higher levels of Gd-IgA1 were found to be independently associated with a greater risk for kidney failure [hazard ratio (HR) = 1.703 per 1 SD, 95% confidence interval (CI) 1.233-2.352; P = 0.001]. Compared with the first Gd-IgA1 quartile group (as reference), the fourth Gd-IgA1 quartile group retained a predictive value for poor renal outcome (HR = 3.740, 95% CI 1.204-11.619; P = 0.023). CONCLUSIONS: These data indicate that Gd-IgA1 levels were similarly elevated in adult patients with IgAN and those with IgAV-N. Moreover, increased Gd-IgA1 levels were associated with both the development and progression of IgAV-N, as observed in IgAN.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Zhang X, Xie X, Shi S, et al. Plasma galactose-deficient immunoglobulin A1 and loss of kidney function in patients with immunoglobulin A vasculitis nephritis. Nephrol Dial Transplant. 2020. PMID: 31377786. doi:10.1093/ndt/gfz151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。